Search Results - envelope

5 Results

Sort By:

Discrete Cross-Reactive Epitopes for Flavivirus Serological Diagnostics and Vaccines

CDC researchers have identified and characterized discrete flavivirus cross-reactive epitopes useful for improving serodiagnosis and vaccination of flaviviruses, such as dengue virus, yellow fever virus, Japanese encephalitis virus, West Nile virus and the tick-borne encephalitis viruses. The flavivirus envelope glycoprotein is one of the primary antigens...

Published: 7/25/2024 | Inventor(s): Wayne Crill, Gwong-Jen Chang

Keywords(s): CDC Docket Import, CDC Docket Import CDC Prosecuting, CHARACTERIZATION, Cross-Reactive, Envelope, Epitopes, Flavivirus, GLYCOPROTEIN, LOCALIZATION, Methods, OID-NCEZID-DVBD, Their, VLXXXX, VOXXXX, WBXXXX, WFXXXX, WIXXXX, WJXXXX, XAXXXX, XCXXXX, XEXXXX, YBXXXX

Category(s): Collaboration Sought > Licensing, Application > Consumer Products, TherapeuticArea > Infectious Disease, TherapeuticArea > Immunology, Application > Occupational Safety and Health, ResearchProducts > Antibodies, Application > Research Materials, Application > Therapeutics, Application > Diagnostics

Viral Like Particles Based Chikungunya Vaccines

Chikungunya virus (CHIKV) is mosquito-borne alphavirus endemic in Africa, India, and Southeast Asia. In 2013 CHIKV infection has also emerged in the Caribbean and a pandemic of CHIKV has re-emerged in the Philippines following Typhoon Haiyan. Currently, there is no vaccine available for the prevention of CHIKV infection and no specific therapy exists...

Published: 7/25/2024 | Inventor(s): Wataru Akahata, Srinivas Rao, Gary Nabel

Keywords(s): Against, ALPHA, ALPHAVIRUS, CAPSID, Chikungunya, CHIKV, DC5BXX, Development, DNA vaccine, E1, E1-E2, E2, Envelope, Generation, Method, MODIFICATION, Modifications, PARTICLES, Patent Category - Biotechnology, PLASMID, PREVENTIVE, production, Protein, proteins, Vaccine, VBXXXX, viral, virus, VIRUS-LIKE, VLPs, VLXXXX, XHXXXX

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Infectious Disease, Application > Vaccines, Application > Diagnostics, ResearchProducts > Research Equipment

Recombinant Sulfated HIV Envelope Protein and Methods for Making Protein

This technology comprises sulfated recombinant gp120 proteins and peptides. Also included are methods for producing sulfated recombinant gp120 proteins. The focus of this technology is on sulfation of two tyrosines in the V2 loop of the HIV major envelope glycoprotein, gp120, which increase the stability of gp120 and promote the synthesis of gp120 protein...

Published: 7/25/2024 | Inventor(s): Raffaello Cimbro, Paolo Lusso

Keywords(s): BETWEEN, CD4, DB4XXX, DBXXXX, DC5XXX, DCXXXX, DXXXXX, Envelope, gp120, HIV, INHIBIT, INTERACTION, Mimics, Peptide, Protein, RECEPTOR, That, V2-loop, VLXXXX, WIXXXX, WJXXXX, WKXXXX, YAXXXX, YBXXXX, YCXXXX, YFXXXX

Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Infectious Disease, Application > Research Materials, Application > Therapeutics, Application > Vaccines

Novel System for HIV-1 Vaccine Development

The available technologies describe specific immunogenic peptides, peptide modifications and methods for identifying additional immunogens against HIV-1 surface proteins, gp120 and gp41. Additionally, detailed methods for use of the described immunogenic peptides in the development of vaccines and diagnostics for HIV-1 are disclosed. The current technologies...

Published: 7/25/2024 | Inventor(s): Peter Kwong

Keywords(s): Against, ANTIGENIC, Anti-HIV-1, ATOMIC, Biotechnology, Broadly, CONFORMATIONALLY, Cryptic, DC5AXX, DC5XXX, DCXXXX, DEFINITION, Details, DXXXXX, Ectodomain, ELICIT, Envelope, Epitope, Epitopes, Epitope-transplant, FUNCTION, Gp120:, gp41, HIV, HIV-1, Immunization, IMMUNOGENS, Level, Membrane-Proximal, Neutralizing, Patent Category - Biotechnology, Reveal, Scaffolds, Stabilized, Strategies, structure, Their, Triggering, V3-Loop, Vaccine

Category(s): Collaboration Sought > Licensing, TherapeuticArea > Infectious Disease, Application > Vaccines

MVA Expressing Modified HIV envelope, gag, and pol Genes

This invention claims Modified Vaccinia Ankara (MVA), a replication-deficient strain of vaccinia virus, expressing Human Immunodeficiency Virus (HIV) env, gag, and pol genes, where the genes are isolated from Ugandan Clade D isolates, Kenyan Clade A isolates, and Tanzanian Clade C isolates. In a rhesus macaque SHIV model, DNA priming followed by a...

Published: 7/25/2024 | Inventor(s): Linda Wyatt, Patricia Earl, Bernard Moss

Keywords(s): (4)r syndrome, 3-@hydroxyacyl-coa dehydrogenase deficiency, Altered, C syndrome, Chromosome 4 ring syndrome, Chromosome 6 ring syndrome, Chromosome 7 ring syndrome, D, DB4AXX, DB4XXX, DBXXXX, DC5AXX, DC5XXX, DCXXXX, DXXXXX, Envelope, Expressing, G syndrome, GAG, GENES, HAD deficiency, HIS deficiency, Histidinemia, HIV, Hyper IgM syndrome, Hypertelorism with esophageal abnormality and hypospadias, Immunodeficiency 2, Immunodeficiency 4, Immunodeficiency-3, MVA, N syndrome, polymerase, R(6) syndrome, R(7) syndrome, Severe combined immunodeficiency, x-linked, Subtype, Syndrome X, W syndrome, W syndrome; Syndrome W, Wiskott Aldrich syndrome

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Infectious Disease, Application > Vaccines